| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_982ec8c822725ebcbfcd8420a7eb36e3 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2008-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2010-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f60961916dd47c48f15a7287ca2f81b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0fb200d4b772b592c1b5d851da8cce9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90d64eba21d3269d29ea9f7a5293b3a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ef0aa44616c96b5a52ab5828f8fd8cb |
| publicationDate |
2010-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2391671-C2 |
| titleOfInvention |
Method of determining early laboratory markers of infection generalisation in patients with acute myeloblastic leukemia in case of neutropenia |
| abstract |
FIELD: medicine. n SUBSTANCE: content of C-reactive protein is determined. If concentration of C-reactive protein is >0.131 g/l development of localised infection into generalised infection in patients with systemic inflammatory response is determined. n EFFECT: increased reliability of determining generalisation of infection in patients with acute myeloblastic leukemia in case of neutropenia. n 1 ex, 2 tbl |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2462711-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2497129-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2535057-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2572704-C1 |
| priorityDate |
2008-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |